What is CereVasc?
CereVasc is a specialized medical technology firm dedicated to the development of novel, minimally invasive treatments for central nervous system disorders. The company's primary innovation, the eShunt System, represents a paradigm shift in the treatment of communicating hydrocephalus. By utilizing a percutaneous transvenous-transdural approach, the eShunt System allows for the implantation of a cerebrospinal fluid shunt without the necessity of traditional, highly invasive neurosurgery. This approach not only reduces patient trauma but also streamlines the procedural workflow for clinicians. Positioned at the intersection of endovascular surgery and neurology, CereVasc is effectively addressing a significant unmet need in the medical device landscape, aiming to improve patient outcomes through precision engineering and advanced delivery components.
How much funding has CereVasc raised?
CereVasc has raised a total of $198.9M across 3 funding rounds:
Series A
$43.9M
Series B
$70M
Series C
$85M
Series A (2020): $43.9M with participation from Perceptive Xontogeny Venture Fund and ATON Partners LLC
Series B (2024): $70M led by Perceptive Xontogeny Venture Fund and Bain Capital Life Sciences
Series C (2026): $85M supported by Johnson & Johnson Innovation and Piper Sandler
Key Investors in CereVasc
Johnson & Johnson Innovation
A global leader in healthcare innovation that partners with early-stage businesses to develop transformational medical solutions across pharmaceuticals and medical devices.
Piper Sandler
A prominent investment bank and institutional securities firm with a deep focus on the healthcare sector, providing capital and advisory services to support growth-stage companies.
Perceptive Xontogeny Venture Fund
A specialized venture capital firm focused on supporting early-to-mid-stage life sciences companies through strategic investment and operational guidance.
What's next for CereVasc?
With the successful closure of this latest financing, CereVasc is well-positioned to scale its clinical operations and refine its manufacturing capabilities. The strategic focus will likely shift toward the completion of pivotal clinical trials and the pursuit of regulatory approvals required for commercialization. As the company moves deeper into its clinical-stage lifecycle, the integration of its eShunt System into standard hospital protocols will be a critical metric for success. Furthermore, the backing from high-profile institutional investors suggests a robust roadmap for future expansion, potentially including the development of additional neuro-interventional platforms that leverage the company's core expertise in endovascular delivery systems. The firm remains focused on maintaining its competitive edge in the neurological device sector through continued research and development excellence.
See full CereVasc company page
